NO20055971L - Cyanofluorpyrrolidinderivat - Google Patents
CyanofluorpyrrolidinderivatInfo
- Publication number
- NO20055971L NO20055971L NO20055971A NO20055971A NO20055971L NO 20055971 L NO20055971 L NO 20055971L NO 20055971 A NO20055971 A NO 20055971A NO 20055971 A NO20055971 A NO 20055971A NO 20055971 L NO20055971 L NO 20055971L
- Authority
- NO
- Norway
- Prior art keywords
- compound
- diseases
- cyanofluorpyrrolidinderivat
- cyanofluoropyrrolidine
- dppiv
- Prior art date
Links
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- -1 cyanofluoropyrrolidine compound Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003137062 | 2003-05-15 | ||
| PCT/JP2004/006983 WO2004101514A1 (ja) | 2003-05-15 | 2004-05-17 | シアノフルオロピロリジン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20055971L true NO20055971L (no) | 2005-12-15 |
Family
ID=33447245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20055971A NO20055971L (no) | 2003-05-15 | 2005-12-15 | Cyanofluorpyrrolidinderivat |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20060293297A1 (es) |
| EP (1) | EP1627870A1 (es) |
| JP (1) | JPWO2004101514A1 (es) |
| KR (1) | KR20060009933A (es) |
| CN (1) | CN1791575A (es) |
| AU (1) | AU2004238719A1 (es) |
| CA (1) | CA2525442A1 (es) |
| MX (1) | MXPA05012274A (es) |
| NO (1) | NO20055971L (es) |
| RU (1) | RU2005139134A (es) |
| WO (1) | WO2004101514A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4959569B2 (ja) | 2004-10-12 | 2012-06-27 | グレンマーク・ファーマシューティカルズ・エスエー | 新規なジペプチジルペプチダーゼｉｖ阻害剤、それらを含む医薬品組成物、およびそれらを調製するためのプロセス |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| DK1942898T4 (da) | 2005-09-14 | 2014-06-02 | Takeda Pharmaceutical | Dipeptidylpeptidase-inhibitorer til behandling af diabetes |
| KR101368988B1 (ko) | 2005-09-16 | 2014-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 디펩티딜 펩티다제 억제제 |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| KR101281962B1 (ko) | 2006-04-11 | 2013-07-08 | 아레나 파마슈티칼스, 인크. | 특정 개체에게서 골 질량을 증가시키는 데에 유용한 화합물을 확인하기 위해 ｇｐｒ119 수용체를 사용하는 방법 |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| US8551524B2 (en) | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| CN103804266B (zh) * | 2014-02-21 | 2016-06-08 | 张家港威胜生物医药有限公司 | 一种维达列汀中间体的合成方法 |
| AU2016229982B2 (en) | 2015-03-09 | 2020-06-18 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| BR112019020485A2 (pt) | 2017-04-03 | 2020-05-12 | Coherus Biosciences, Inc. | Agonista ppary para tratamento de paralisia supranuclear progressiva |
| CN108164528B (zh) * | 2018-03-31 | 2019-03-22 | 杭州巴洛特生物科技有限公司 | 一种酰胺类衍生物及其在高血压、高血脂和动脉粥样硬化中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| TWI243162B (en) * | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| JP2004026820A (ja) * | 2002-05-09 | 2004-01-29 | Taisho Pharmaceut Co Ltd | ジペプチジルペプチダーゼｉｖ阻害剤 |
| JPWO2003095425A1 (ja) * | 2002-05-09 | 2005-09-15 | 大正製薬株式会社 | シアノピロリジン誘導体 |
-
2004
- 2004-05-17 US US10/556,896 patent/US20060293297A1/en not_active Abandoned
- 2004-05-17 JP JP2005506281A patent/JPWO2004101514A1/ja not_active Withdrawn
- 2004-05-17 CA CA002525442A patent/CA2525442A1/en not_active Abandoned
- 2004-05-17 MX MXPA05012274A patent/MXPA05012274A/es not_active Application Discontinuation
- 2004-05-17 WO PCT/JP2004/006983 patent/WO2004101514A1/ja not_active Application Discontinuation
- 2004-05-17 KR KR1020057021698A patent/KR20060009933A/ko not_active Application Discontinuation
- 2004-05-17 AU AU2004238719A patent/AU2004238719A1/en not_active Abandoned
- 2004-05-17 RU RU2005139134/04A patent/RU2005139134A/ru not_active Application Discontinuation
- 2004-05-17 EP EP04733467A patent/EP1627870A1/en not_active Withdrawn
- 2004-05-17 CN CNA200480013353XA patent/CN1791575A/zh active Pending
-
2005
- 2005-12-15 NO NO20055971A patent/NO20055971L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1627870A1 (en) | 2006-02-22 |
| KR20060009933A (ko) | 2006-02-01 |
| JPWO2004101514A1 (ja) | 2006-07-13 |
| CN1791575A (zh) | 2006-06-21 |
| MXPA05012274A (es) | 2006-02-10 |
| AU2004238719A1 (en) | 2004-11-25 |
| WO2004101514A1 (ja) | 2004-11-25 |
| US20060293297A1 (en) | 2006-12-28 |
| CA2525442A1 (en) | 2004-11-25 |
| RU2005139134A (ru) | 2006-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20055971L (no) | Cyanofluorpyrrolidinderivat | |
| WO2004037181A3 (en) | Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods | |
| YU34404A (sh) | N-supstituisani derivati pirolidina kao inhibitori dipeptidil-peptidaze iv | |
| TW200500341A (en) | Novel compounds | |
| NO20055649L (no) | Substituert dihydrokinazolin med antiviale egenskaper | |
| WO2003000180A3 (en) | Dipeptidyl peptidase inhibitors for the treatment of diabetes | |
| NO20055680L (no) | Heksahydropyridoisokinoliner som DPP-IV-inhibitorer | |
| CA2474578A1 (en) | Novel pyridin- and pyrimidin-derivatives | |
| MX2009006742A (es) | Inhibidores acilaminopirazoles como fgfr. | |
| WO2003000181A3 (en) | Dipeptidyl peptidase inhibitors for the treatment of diabetes | |
| TW200505919A (en) | DPP-IV inhibitors | |
| NO20060706L (no) | Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease | |
| CA2407100A1 (en) | 1-aroyl-piperidinyl benzamidines | |
| WO2007071396A3 (en) | Pyrazinoylguanidine compounds useful in the treatment of inflammatory or allergic conditions | |
| WO2003002593A3 (en) | Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis | |
| GEP20084403B (en) | C-aryl glucoside sglt2 inhibitors and method | |
| GB0225475D0 (en) | Therapeutic agents | |
| PT1928499E (pt) | Utilização de um inibidor da dpp-iv para reduzir eventos hipoglicémicos | |
| MY136761A (en) | Oxazol derivatives | |
| WO2004037789A3 (en) | Methylene urea derivatives as raf-kinase inhibitors | |
| MXPA04004548A (es) | Acidos heteroarilalalcanoicos substituidos y su uso como inhibidores de aldosa reductasa. | |
| GB0413087D0 (en) | Therapeutic compounds | |
| MXPA02003977A (es) | Inhibidores de adhesion de celula mediada por al°2. | |
| MXPA04006041A (es) | Antivirales de piridoquinoxalina. | |
| UA87822C2 (ru) | Производные нафтилена как ингибиторы цитохрома p450 |